AICPA Audit Guide, Government Auditing Standards and Single Audits 2018 Edition - Summary of Illustrative Audit Report Changes

Similar documents
Alert That Restricts the Use of the Auditor s Written Communication

Attributes Statistical Sampling Tables

SAS 112: Communicating Internal Control Related Matters Identified in an Audit

Is Your Sample Representative?

IAASB Main Agenda (March 2005) Page Agenda Item. DRAFT EXPLANATORY MEMORANDUM ISA 701 and ISA 702 Exposure Drafts February 2005

IAASB Main Agenda (September 2005) Page Agenda Item. Analysis of ISA 330 and Mapping Document

Assurance Engagements Other Than Audits or Reviews of Historical Financial Information

Basis for Conclusions: ISA 500 (Redrafted), Audit Evidence

Exposure Draft, ISA 720 (Revised) The Auditor s Responsibilities Relating to Other Information


ISA 540, Auditing Accounting Estimates, Including Fair Value Accounting Estimates, and Related Disclosures Issues and Task Force Recommendations

ISA 315 (Revised) Identifying and Assessing the Risks of Material Misstatement through Understanding the Entity and Its Environment

Auditing Standards and Practices Council

International Framework for Assurance Engagements

Individual Unit Function: Ecology Procedure No.: EC-13 Page: 1 of 5. Preparer: Owner: Approver: SIH Team Leader EHS Team Leader EHS Hub Director

INTERNATIONAL STANDARD ON ASSURANCE ENGAGEMENTS 3000 ASSURANCE ENGAGEMENTS OTHER THAN AUDITS OR REVIEWS OF HISTORICAL FINANCIAL INFORMATION CONTENTS

Re: JICPA comments on the IESBA Consultation Paper Improving the Structure of the Code of Ethics for Professional Accountants

Assurance Engagements Other than Audits or Review of Historical Financial Statements

14 February Tower Old Broad Street London EC2N 1HQ United Kingdom t + 44 (0) f + 44 (0)

Basis for Conclusions: ISA 530 (Redrafted), Audit Sampling

ADMINISTRATIVE POLICY AND PROCEDURES MedStar Family Choice Medicare Advantage Plans

Health (Tobacco, Nicotine etc. and Care) (Scotland) Act 2016

UKAS Guidance on the Application of ISO/IEC Dealing with Expressions of Opinions and Interpretations

9-A ISA 260 (Revised and Redrafted) Significant Issues

DON M. PALLAIS, CPA 14 Dahlgren Road Richmond, Virginia Telephone: (804) Fax: (804)

11 September Tower Old Broad Street London EC2N 1HQ United Kingdom t + 44 (0) f + 44 (0)

Self-Evaluation and Attestation

32 CFR (a)(4), (a)(6)(iii), and (a)(6)(iv)

NANDTB-F012 Rev 0 Audit Checklist

DISCLOSURE OF ALCOHOL AND SUBSTANCE/DRUG ABUSE RECORDS. This Policy describes permissible disclosures of Alcohol and Substance/Drug Abuse Records.

RFQ:-HPCSA 03/2017 REQUEST FOR QUOTATION FOR OCCUPATIONAL HEALTH SERVICE ON BEHALF OF THE HEALTH PROFESSIONS COUNCIL OF SOUTH AFRICA

Independent Assurance Statement by Bureau Veritas

15 May 2017 Exposure Draft. Response Due Date 23 June Exposure Draft

Z E N I T H M E D I C A L P R O V I D E R N E T W O R K P O L I C Y Title: Provider Appeal of Network Exclusion Policy

Cutanea Life Sciences, Inc. Comprehensive Compliance Program

COUNCIL OF THE EUROPEAN UNION. Brussels, 7 September 2009 (OR. en) 11261/09 Interinstitutional File: 2008/0002 (COD) DENLEG 51 CODEC 893

Chapter 15 Section 1

CARD/MAIL/PRE-APPROVAL/PREFERRED RIDER FOR PRESCRIPTION DRUG [INSURANCE] [Policy]holder: Group Policy No: Effective Date:

INTERNATIONAL STANDARD ON AUDITING (NEW ZEALAND) 530

COMMISSION REGULATION (EU)

Subtitle E--National Bioengineered Food Disclosure Standard

Objectives. Training Goals Content Objective. Language Objective

Standard Guide for Evaluating Capabilities of Nondestructive Testing Agencies 1

Texasmutual.com 844-WORKSAFE ( ) January 2016 Worksafetexas.com 1

This follows similar work previously conducted by Bureau Veritas for Nestlé S.A. in other global operations.

Seal of Approval Guidelines. The Approval Program

******************************************************************* MINUTES OF SYMMES TOWNSHIP SPECIAL MEETING

TERMS AND CONDITIONS NATIONAL GOOD LABORATORY PRACTICE (GLP) COMPLIANCE MONITORING AUTHORITY

LAB5 EDITION 2 NOVEMBER 2012

Analysis of Responses to Question 5 of the Exposure Draft

Clinical Policy: Roflumilast (Daliresp) Reference Number: CP.PMN.46. Line of Business: Medicaid

CMS Rulings. Department of Health and Human Services. Centers for Medicare & Medicaid Services. Ruling No Date: May 3, 2005

Family Tariff. General Tariff Information. Scope of the family referral. Extended Services

RULES. on Selection and Sale of Tobacco and Trade Terms with Suppliers CHAPTER I

Answers to Questions for RFP American Sign Language Interpreter

Practical guidance for applicants on the submission of applications on food additives, food enzymes and food flavourings

CHAPTER 4 POST-MARKETING SURVEILLANCE OF DRUGS

SCOPE OF PRACTICE AND STRUCTURED PROFESSIONAL RELATIONSHIP

Fiona Campbell. ISA 315 (Revised) Responding to Comments to the Exposure Draft. Deputy Chair of the IAASB and Chair of the ISA 315 Task Force

SRI LANKA AUDITING STANDARD 530 AUDIT SAMPLING CONTENTS

SENATE, No STATE OF NEW JERSEY. 217th LEGISLATURE INTRODUCED FEBRUARY 8, 2016

Ministry of Health and Long-Term Care Overdose Prevention Sites: User Guide for Applicants

International Standard on Auditing (UK) 530

Basis for Conclusions: ISA 230 (Redrafted), Audit Documentation

RADIESSE Volumizing Filler E-Media Kit Terms of Use PERMISSION TO USE MERZ AESTHETICS COPYRIGHTED MATERIAL AND TRADEMARKS

SUBJECT: Civilian Employee Alcohol and Drug Abuse Prevention, Testing, and Control Program

Name of Event: Date of Event: Details of Event Organiser: [Name, Address, Contact number, ]

RE: IESBA s Exposure Draft Proposed Revisions Pertaining to Safeguards in the Code Phase 1

TRANSLATION. Montreal, April 11, 2011

Enhanced service specification Childhood seasonal influenza vaccination programme NHS England gateway reference: 01641

BEFORE THE IOWA BOARD OF PHARMACY ) RECOMMENDATION TO THE ) RE: CANNABIDIOL AND IOWA GENERAL ASSEMBLY ) MARIJUANA ) FACTUAL AND LEGAL BACKGROUND

USE OF ALCOHOLIC BEVERAGES ON CAMPUS GUIDELINES

Standard FAC Establish and Communicate System Operating Limits

NBCCEDP Program Manual: NBCCEDP Policies and Procedures Chapter

SECTION PRESCRIPTIONS

PHYSIOTHERAPY ACT AUTHORIZATION REGULATIONS

DIRECTIVE 2004/24/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL. of 31 March 2004

Independent Assurance Statement by Bureau Veritas

USE OF ILLICIT DRUGS AND OTHER PROHIBITED SUBSTANCES BY STUDENTS

This document is meant purely as documentation tool and the institutions do not assume any liability for its contents

Code of Practice on Authorship

Clinical Policy: Acitretin (Soriatane) Reference Number: CP.PMN.40. Line of Business: Medicaid

IAASB Main Agenda (February 2007) Page Agenda Item PROPOSED INTERNATIONAL STANDARD ON AUDITING 530 (REDRAFTED)

This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents

Testing Railway Safety Critical Workers for Drugs and Alcohol

2017 FDA Food Code. FDA/CFSAN Retail Food Policy Team

COMPETENT AUTHORITY (UK) MEDICAL DEVICES DIRECTIVES GUIDANCE NOTES FOR MANUFACTURERS OF DENTAL APPLIANCES

DATE: August 17, Document Title: Amendment to PIN Regarding Affiliation Agreements of Community and Migrant Health Centers

545 Fifth Avenue, 14th Floor Tel: +1 (212) New York, New York Fax: +1 (212) Internet:

BEFORE THE NORTH CAROLINA MEDICAL BOARD. In re: ) ) Marcono Raymond Hines, M.D. ) CONSENT ORDER ) Respondent. )

Enhanced Service Specification. Childhood seasonal influenza vaccination programme 2018/19

Pursuant to the authority vested in the Commissioner of Health by section 3369-a of the Public

Environmental, Health and Safety

Clinical Policy: Sodium Oxybate (Xyrem) Reference Number: CP.PMN.42. Line of Business: Medicaid

KEYSTONE HEALTH PLAN EAST, INC. (hereafter called "Keystone" or Health Benefits Plan or Claims Administrator ) RIDER

TG Approved By: SANAS Page 1 of 6

MEMBERSHIP APPLICATION INSTRUCTIONS

Some of the benefits to your entity as a member of the Local Government Testing Consortium (LGTC), are as follows:

Transcription:

The 2018 edition of the AICPA Audit Guide, Government Auditing Standards and Single Audits, revised certain of the illustrative reports included in chapters 4, 13 and 14 of the guide. The changes were made to ensure consistency between all reports and are largely editorial in nature. The GAQC has developed this non-authoritative summary 1 of the changes to assist members in updating their report templates. The following identifies the section of each report that changed and the markup of the changes. As a reminder, selected illustrative audit reports from the 2018 edition of the guide are available in their entirety on GAQC s Illustrative Auditor s Report page. Example 4-1 No changes Example 4-2 Chapter 4 Report Changes Section Other Reporting Required by Government Auditing Standards In accordance with Government Auditing Standards, we have also issued our report dated [date of report] on our consideration of Example NFP s internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Example NFP s City of Example s internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with Government Auditing Standards in considering Example NFP s internal control over financial reporting and compliance. Example 4-3, Example 4-4, Example 4-5, Example 4-6 and Example 4-7 Section - Internal Control Over Financial Reporting (2 nd paragraph) A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A material 1 This document has been developed for the convenience of our members but is nonauthoritative. Auditors should consult the original AICPA auditing standards and the 2018 AICPA Audit Guide, Government Auditing Standards and Single Audits, in its entirety when developing audit reports. Page 1 of 6

weakness is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity s financial statements will not be prevented, or detected and corrected, on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance. Example 4-4, Example 4-5, Example 4-6, Example 4-7 and Example 4-8 Section Purpose of this Report The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity s internal control or on compliance. This report is an integral part of an audit performed in accordance with Government Auditing Standards in considering the entity s internal control and compliance. Accordingly, this communication is not suitable for any other purpose. Example 4-5, Example 4-6 and Example 4-7 Section Internal Control Over Financial Reporting (3 rd paragraph) Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies and therefore, material weaknesses or significant deficiencies may exist that have not been identified. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. We did identify certain deficiencies in internal control, described in the accompanying [include the title of the schedule in which the findings are reported (e.g., schedule of findings and responses or schedule of findings and questioned costs)] as items [list the reference numbers of the related findings, for example, 20X1-001, 20X1-003, and 20X1-004] that we consider to be significant deficiencies. [List the reference numbers of the related findings, for example, 20X1-001, 20X1-003, and 20X1-004]. Formatted: Font: Italic Example 4-8 and Example 4-9 Section Internal Control Over Financial Reporting (paragraphs 2 through 4) Our consideration of internal control was for the limited purpose described in the preceding paragraph and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies and therefore, material weaknesses or significant deficiencies may exist that have not been identified. However, Page 2 of 6

as described in the accompanying [include the title of the schedule in which the findings are reported (e.g., schedule of findings and responses or schedule of findings and questioned costs], we did identify identified certain deficiencies in internal control that we consider to be material weaknesses and significant deficiencies. A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A material weakness is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity s financial statements will not be prevented, or detected and corrected, on a timely basis. We consider the deficiencies described in the accompanying [include the title of the schedule in which the findings are reported (e.g., schedule of findings and responses or schedule of findings and questioned costs)] as items [list the reference numbers of the related findings, for example, 20X1-001, 20X1-003, and 20X1-004]to be material weaknesses. [List the reference numbers of the related findings, for example, 20X1-001, 20X1-003, and 20X1-004]. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness yet important enough to merit attention by those charged with governance. We consider the deficiencies described in the accompanying [include the title of the schedule in which the findings are reported (e.g. schedule of findings and responses or schedule of findings and questioned costs)] as items [list the reference numbers of the related findings, for example, 20X1-002 and 20X2-005] to be significant deficiencies. (List the reference numbers of the related findings, for example, 20X1-002 and 20X1-005.)] Formatted: Font: Italic Formatted: Font: Italic Example 4-5, Example 4-6, Example 4-7 and Example 4-8 Section Example Entity s Response to Findings Example Entity s response to the findings identified in our audit isare described in the accompanying [include the title of the schedule in which the findings are reported (e.g., schedule of findings and responses or schedule of findings and questioned costs) "or previously" if findings and responses are included in the body of the report]. Example Entity s response was not subjected to the auditing procedures applied in the audit of the financial statements and, accordingly, we express no opinion on it. Page 3 of 6

Chapter 13 Reports Example 13-1, Example 13-2, Example 13-3, Example 13-4, Example 13-5, Example 13-6 Section Other Matters (2 nd paragraph of Example 13-4, Example 13-5 and Example 13-6) Example Entity s response to the noncompliance findings identified in our audit isare described in the accompanying [insert name of document containing management s response to the auditor s findings; for example, schedule of findings and questioned costs and/or corrective action plan.] Example Entity s response was not subjected to the auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response. Example 13-2 and Example 13-3 Section Report on Internal Control Over Compliance (paragraphs 3 and 4) Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies and therefore, material weaknesses or significant deficiencies may exist that have not been identified. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, we did identifyidentified certain deficiencies in internal control over compliance, as described in the accompanying schedule of findings and questioned costs as items [list the reference numbers of the related findings, for example, 20X1-003, 20X1-004, and 20X1-005], that we consider to be significant deficiencies. Example Entity s response to the internal control over compliance findings identified in our audit isare described in the accompanying [insert name of document containing management s response to the auditor s findings; for example, schedule of findings and questioned costs and/or corrective action plan]. Example Entity s response was not subjected to the auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response. Page 4 of 6

Example 13-4 and Example 13-6 Section Report on Internal Control Over Compliance (paragraphs 2 and 5) Our consideration of internal control over compliance was for the limited purpose described in the preceding paragraph and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies and therefore, material weaknesses or significant deficiencies may exist that have not been identified. However, as discussed below, we did identifyidentified certain deficiencies in internal control over compliance that we consider to be material weaknesses and significant deficiencies. Example Entity s response to the internal control over compliance findings identified in our audit isare described in the accompanying [insert name of document containing management s response to the auditor s findings; for example, schedule of findings and questioned costs and/or corrective action plan]. Example Entity s response was not subjected to the auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response. Example 13-5 Section Internal Control Over Compliance (paragraphs 3 and 4) Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies and therefore, material weaknesses or significant deficiencies may exist that have not been identified. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, we did identifyidentified certain deficiencies in internal control over compliance, as described in the accompanying schedule of findings and questioned costs as items [list the reference numbers of the related findings, for example, 20X1-005, 20X1-006, and 20X1-007] that we consider to be significant deficiencies. Example Entity s response to the internal control over compliance findings identified in our audit isare described in the accompanying [insert name of document containing management s response to the auditor s findings; for example, schedule of findings and questioned costs and/or corrective action plan]. Example Entity s response was not subjected to the auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response. Page 5 of 6

Chapter 14 Reports Example 14-2 Section - Other Matters Example Entity's response to the noncompliance findings identified in our audit isare described in the accompanying [insert name of document containing management s response to audit findings; for example, schedule of findings and questioned costs and/or corrective action plan]. Example Entity's response was not subjected to the auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response. Page 6 of 6